NCT01690403View on ClinicalTrials.gov

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Tuberculosis
Interventions
DRUG

rifapentine (M000473)

"Pharmaceutical form:tablet~Route of administration: oral"

DRUG

EFZ EMT TDF

"Pharmaceutical form:tablet~Route of administration: oral"

Trial Locations (1)

14202

Investigational Site Number 840001, Buffalo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01690403 - Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients | Biotech Hunter | Biotech Hunter